• Career that spans biotech and pharma including at Astex Pharmaceuticals and GSK
• Has led discovery of over 10 drugs taken into clinical development, including the two recent drugs from the Astex stable that have received marketing approval
• Will grow in-house drug development team to harness power of AI and take rare disease treatments from prediction through to the clinical stage
News
Westbury, NY – July 10, 2019 – BioIVT, a leading provider of research models and services for drug and diagnostic development, today announced that it is hosting a webinar that will present the latest in vitro research methods and International Transporter Consortium (ITC) guidance for assessing bile salt export pump (BSEP) inhibition to reduce and manage the risk of drug-induced liver injury (DILI) during drug development.
Invest Newcastle has welcomed a senior Cuban life science business delegation to the region for a two-day visit. They used this opportunity to show off the city’s life science strengths and world-leading universities.
AMSBIO announce new, best-in-class CAR-T cells, engineered CAR-T target cells, PBMC, cell media and activation beads in response to the rapid growth in research on the therapeutic uses of CAR-T cells.
All CAR-T cell products from AMSBIO are T cells produced from either a group of donors or from individual donor transduced with CAR (Chimeric antigen receptor) - lentivirus.
SOMERSET, N.J. – July 9, 2019 — Catalent, Inc.
Cambridge, UK, 4th July, 2019: We are delighted to announce Sunil Shah, CEO, o2h Ventures, has won the prestigious UKBAA Angel Investor of the Year Award for his active participation in backing high growth potential startups and early-stage businesses in the UK. Sunil’s contribution has been instrumental in the growth of biotech in UK. He has been investing into the biotech therapeutics sector since many years – a sector from which traditionally many angel investors have stayed away.
Arecor Limited (“Arecor” or “the Company”), the specialty pharmaceutical company leveraging its innovative and proprietary formulation technology to develop superior treatments for a range of disease areas, including diabetes, today announces that it has signed a further collaboration with a major global pharmaceutical company.
On Thursday 4 July Dr. Fiona Marshall, Global Head of Neuroscience Discovery, MSD visited Newcastle to mark the official launch of The Biosphere.
Located at Newcastle Helix, The Biosphere is a specialist lab facility tailored to commercialisation of life sciences. It provides biology and chemistry laboratories and high-quality office space.
Cambridge, UK, 08 July 2019: PhoreMost, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, today announced it has entered into a structural biology focussed collaboration with the Centre for Chemical Biology and Therapeutics (CCBT), Bangalore, India. CCBT at the Institute for Stem Cell Science and Regenerative Medicine (inStem) is funded by the Department of Biotechnology, Government of India,.
Cambridge, UK, 8 July 2019: Horizon Discovery Group plc (LSE: HZD) (“Horizon”), a company driving the application of gene editing and gene modulation within the global life science market, today announced that Celyad (Euronext Brussels and Paris, and Nasdaq: CYAD), a clinical-stage biopharmaceutical company focused on the development of CAR-T cell-based therapies, received FDA Acceptance of Investigational New Drug (IND) application for the autologous NKG2D based CAR-T cell therapy CYAD-02 that deploys Horizon’s optimized SMARTvector™ shRNA technology.